Seer (NASDAQ:SEER) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Seer (NASDAQ:SEER) announced its earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03, FiscalAI reports. The business had revenue of $4.20 million during the quarter, compared to analysts’ expectations of $4.60 million. Seer had a negative net margin of 484.51% and a negative return on equity of 25.88%.

Here are the key takeaways from Seer’s conference call:

• Q4 revenue was $4.2M and full‑year 2025 revenue was $16.6M (17% YoY) but missed expectations due to customer budget pressures and delayed NIH funding; guidance for 2026 is $16–$18M, reflecting limited near‑term growth visibility.
• Commercial momentum — installed base grew 67% to 82 instruments, consumable kit volume rose ~69%, total revenue excluding related‑party sales grew ~33%, and the Proteograph was selected for multiple population‑scale studies (including 20k and 10k sample projects) while cumulative publications nearly doubled to 70.
• Product roadmap and innovation — launched the Proteograph ONE assay and SP200 automation, plans to release PAS v4 with an LLM chat interface later this year, is developing a proteoform profiling assay for 2027, and expects next‑generation detector/platform data in H2 2026.
• Strong financial runway and shareholder returns — ended the year with ~$241M cash and investments, improved free‑cash‑flow loss to ~$45.6M, believes it has capital to reach breakeven, repurchased ~11.7M shares and the board authorized an additional $25M repurchase, and adopted a plan to preserve ~$262M of NOL tax assets.

Seer Stock Down 0.5%

SEER traded down $0.01 during trading hours on Thursday, reaching $2.08. The company’s stock had a trading volume of 673,128 shares, compared to its average volume of 338,944. The company’s 50-day moving average is $1.89 and its 200-day moving average is $2.02. Seer has a 52 week low of $1.62 and a 52 week high of $2.41.

Institutional Investors Weigh In On Seer

A number of institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP lifted its position in shares of Seer by 2.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company’s stock valued at $431,000 after acquiring an additional 6,304 shares during the period. Shay Capital LLC increased its position in shares of Seer by 17.7% in the third quarter. Shay Capital LLC now owns 73,571 shares of the company’s stock worth $160,000 after purchasing an additional 11,073 shares during the period. Occudo Quantitative Strategies LP acquired a new position in Seer in the second quarter valued at about $25,000. Vanguard Group Inc. lifted its position in Seer by 0.9% during the third quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company’s stock worth $4,820,000 after purchasing an additional 18,760 shares during the period. Finally, Corient Private Wealth LLC grew its stake in Seer by 46.3% during the second quarter. Corient Private Wealth LLC now owns 63,200 shares of the company’s stock worth $135,000 after buying an additional 20,000 shares in the last quarter. Institutional investors own 75.20% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on SEER. Wall Street Zen upgraded Seer to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Seer currently has an average rating of “Sell”.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.